Oncotelic Therapeutics (OTCQB: OTLC) announced the launch of its artificial intelligence-powered good manufacturing practices (GMP) manufacturing services platform at the 2026 BIO International Convention in San Diego. The platform integrates the company's PDAOAI technology with advanced robotics provided through its collaboration with TechForce Robotics, aiming to support pharmaceutical, biotechnology, and advanced therapeutics companies in modernizing their manufacturing operations through AI-driven workflows, digital quality systems, and intelligent automation.
According to the company, the platform is designed to facilitate electronic batch records, manufacturing documentation, GMP workflow digitization, quality and compliance functions, and process monitoring. Oncotelic also plans to showcase progress with its Deciparticle nanomedicine platform, including SAPU003, a clinical-stage intravenous everolimus program currently under evaluation in a Phase 1b study. The full press release is available at https://ibn.fm/upnBW.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products for high-unmet-need cancers and rare pediatric indications. The company's pipeline includes innovative late-stage therapeutic candidates. In addition to its directly owned drug pipeline, Oncotelic benefits from the extensive patent portfolio of its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued U.S. patents. The company also licenses and co-develops drug candidates through joint ventures; it currently owns 45% of GMP Bio, a joint venture advancing its own pipeline of drug candidates that complement Oncotelic's strategic position in oncology and rare disease therapeutics.
Oncotelic also develops PDAOAI, its proprietary AI platform for drug discovery, lab automation, and AI-assisted GMP manufacturing. Through its relationship with SAPU Bio, an OEB-5 sterile injectable cGMP manufacturing facility, PDAOAI underpins the platform and its ongoing joint development work with TechForce Robotics, Oncotelic's strategic robotics and automation partner. TechForce Robotics, the operating brand of Nightfood Holdings, Inc., designs and deploys purpose-built robotics and automation solutions for service, hospitality, and pharmaceutical manufacturing applications. More information is available at https://www.techforcerobotics.com.
This launch represents a significant step in integrating AI and robotics into pharmaceutical manufacturing, potentially reducing costs and improving compliance for drug developers. The platform's focus on digitization and automation could help address longstanding inefficiencies in GMP manufacturing, making it easier for smaller biotech firms to bring therapies to market. The latest news and updates regarding Oncotelic can be found in the company's newsroom at https://ibn.fm/OTLC.
